Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mindset Pharma Inc (OP:MSSTF)

N/A UNCHANGED
Last Price Updated: 3:55 PM EDT, Oct 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mindset Pharma Inc

< Previous 1 2 3 4 Next >
News headline image
Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic ↗
Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase 2 study of RE104, a novel serotonergic... 
Via Benzinga
News headline image
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
News headline image
Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions ↗
Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka... 
Via Benzinga
News headline image
Terran Biosciences Steps Into 4-OH-DiPT Prodrug Arena With New Patent Application ↗
As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also... 
Via Benzinga
News headline image
Reunion Neuroscience On The Brink Of Going Private With Final Court Approval ↗
Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution... 
Via Benzinga
News headline image
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
News headline image
Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3 ↗
Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ: REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates. Here's a breakdown of the... 
Via Benzinga
News headline image
UK Greenlights Phase 2 Clinical Trial On Mindset Pharma's Psilocin Drug For Major Depression ↗
Drug discovery company Mindset Pharma (OTCQB: MSSTF) received approval from the U.K. 
Via Benzinga
News headline image
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More ↗
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
Via Benzinga
News headline image
This Firm Bets On Non-Hallucinogenic Psychedelics, Files Claims For International IP Protection ↗
Numerous biopharma companies are working on enhancing first-generation or “classical” psychedelics. They're tuning down the side effects, and protecting their findings along the way. 
Via Benzinga
News headline image
New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market ↗
Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual... 
Via Benzinga
News headline image
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More ↗
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
News headline image
Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court ↗
Clinical-stage biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) filed a lawsuit against drug discovery business Mindset Pharma Inc. (OTCQB: MSSTF) in the District Court of New Jersey. 
Via Benzinga
News headline image
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More ↗
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
Via Benzinga
News headline image
Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla ↗
The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia. 
Via Benzinga
News headline image
Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded ↗
Silo Pharma Sees Growth In IP With New US Patent For Novel Ketamine Method On Stress-Induced Affective Disorders 
Via Benzinga
News headline image
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More ↗
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? 
Via Benzinga
News headline image
Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News ↗
Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for... 
Via Benzinga
News headline image
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More ↗
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
News headline image
These Two Psychedelics Companies Team Up In An Exclusive Sales Deal, Here Are The Details ↗
Next-gen psychedelics producers Mindset Pharma Inc. (OTCQB: MSSTF) and PharmAla Biotech Holdings Inc. 
Via Benzinga
News headline image
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
PharmAla will be the exclusive global reseller of Mindset’s cGMP psilocybin to appropriately licensed clinical researchers 
From PharmAla Biotech
Via GlobeNewswire
News headline image
EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance ↗
(Part four of a four-part series) See previous stories in this series:  
Via Benzinga
News headline image
European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed ↗
UK psychedelics clinical research organization Clerkenwell Health raised $2.047.710 (£2.1 million) in seed funding, bringing the total to date up to $2.437.750 (£2.5 million), all of which will be used... 
Via Benzinga
News headline image
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More ↗
Alberta Becomes The First Canadian Province To Regulate Psychedelics-Assisted Therapy 
Via Benzinga
News headline image
Next-Generation Psychedelics Shows Promise With Upcoming Clinical Trials ↗
Biopharma R&D company Mindset Pharma Inc. 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family ↗
Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc. 
Via Benzinga
News headline image
Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close? ↗
Biotech drug discovery firm Mindset Pharma Inc. 
Via Benzinga
News headline image
Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries ↗
Psychedelics R&D company Mindset Pharma (OTCQB: MSSTF) has filed no less than 16 national applications, including countries within the main South East Asian markets, for one of its key families of... 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From September 7, 2022 ↗
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 5.66% at $1.12 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.